(PR-inside.com)
COPENHAGEN, Denmark, March 8, 2018 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today announced a new Phase 2 study, exploring the combination of its cancer vaccine, CV301 and Bristol-Myers Squibb's nivolumab (OPDIVO) in patients with metastatic colorectal cancer (mCRC). CV301 is specifically designed to elicit T-cells against the tumor antigens CEA and MUC1, both of ..
More...
- Bavarian Nordic and Bristol-Myers Squibb agree to supply clinical material for the trial
- Investigator-led study represents the fourth clinical combination of CV301 with a checkpoint inhibitor
COPENHAGEN, Denmark, March 8, 2018 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today announced a new Phase 2 study, exploring the combination of its cancer vaccine, CV301 and Bristol-Myers Squibb's nivolumab (OPDIVO) in patients with metastatic colorectal cancer (mCRC). CV301 is specifically designed to elicit T-cells against the tumor antigens CEA and MUC1, both of ..
More...